Ikelan (Atenolol)

• Atenolol is indicated for several cardiovascular conditions that involve elevated blood pressure or cardiac workload.
• Hypertension: reduces systolic and diastolic blood pressure, helping to prevent complications.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest‑pain episodes.
• Post‑myocardial infarction prophylaxis: lowers risk of recurrent infarction and improves survival.
• Cardiac arrhythmias: controls heart rate in certain supraventricular tachyarrhythmias.

• Atenolol selectively blocks β1‑adrenergic receptors in cardiac tissue, preventing catecholamine binding. This antagonism reduces cyclic AMP formation, leading to decreased intracellular calcium, which slows sinoatrial node firing and diminishes myocardial contractility. The resultant lower heart rate and contractile force reduce cardiac output and peripheral vascular resistance, contributing to blood pressure reduction. By limiting sympathetic stimulation, atenolol also improves ventricular filling time and can attenuate renin release from the kidneys.

Atenolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Fatigue or general weakness.
• Dizziness or light‑headedness, especially on standing.
• Cold extremities such as hands and feet.
• Bradycardia (slow heart rate).
• Mild gastrointestinal upset (nausea, abdominal discomfort).
• Sleep disturbances or vivid dreams.

Serious or Rare Side Effects

• Bronchospasm, particularly in patients with asthma or COPD.
• Severe hypotension leading to fainting.
• High‑grade heart block or atrioventricular conduction disturbances.
• Allergic reactions including rash, itching or angioedema.
• Depression or mood changes.
• Hepatic dysfunction manifested by abnormal liver enzymes.

• When prescribing atenolol, clinicians should consider several precautionary measures to ensure safe use.
• Assess cardiovascular status: evaluate baseline heart rate and blood pressure before initiation.
• Monitor renal and hepatic function: dose adjustment may be needed in impairment.
• Caution in asthma or COPD: β1 selectivity may still affect bronchial tone.
• Review concomitant medications: avoid combining with other negative chronotropes without monitoring.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Atenolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Co‑administration with other β‑blockers may cause excessive bradycardia.
• Combination with calcium‑channel blockers such as verapamil can lead to profound hypotension.
• Potent CYP2D6 inhibitors (e.g., quinidine, paroxetine) may increase atenolol plasma levels.

Moderate Interactions (Monitor Closely)

• NSAIDs may blunt antihypertensive effect.
• Diuretics can enhance hypotensive response.
• Insulin or oral hypoglycemics may have hypoglycemia symptoms masked.
• Certain antidepressants (e.g., tricyclics) may increase risk of bradycardia.